

Trials clinici attivati nel 2022

Data di Inizio	Responsabile	Denominazione
27/05/2022	CIARDIELLO Fortunato	STUDIO DI FASE 3, IN APERTO, MULTICENTRICO, RANDOMIZZATO DI ENCORAFENIB E CETUXIMAB IN PRIMA LINEA CON O SENZA CHEMIOTERAPIA RISPETTO ALLO STANDARD TERAPEUTICO CON UNA FASE DI SAFETY LEAD-IN (SLI) DI ENCORAFENIB E CETUXIMAB IN COMBINAZIONE CON LA CHEMIOTERAPIA IN PARTECIPANTI CON TUMORE COLORETTALE METASTATICO BRAF V600E MUTATO
22/03/2022	CIARDIELLO Fortunato	A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer
31/01/2022	CIARDIELLO Fortunato	Studio di fase III in pazienti con tumore del colon-retto metastatico, RAS/BRAF Wild type sul tessuto tumorale e RAS mutato su biopsia liquida con l'obiettivo di confrontare una terapia di prima linea con schema Folfiri in associazione a Cetuximab o Bevacizumab
20/06/2022	CIARDIELLO Fortunato	Studio Clinico di Fase 2 In Aperto per Valutare Sicurezza ed Efficacia di Telisotuzumab Vedotin (ABBV-399) in Soggetti Affetti da Carcinoma Polmonare Non a Piccole Cellule c-Met+ precedentemente trattato
13/10/2022	CIARDIELLO Fortunato	A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
03/10/2022	CIARDIELLO Fortunato	Phase 1/2 Clinical Trial of MRTX849 in Patients with KRAS G12C+ Tumors Initial Data Shows Overall Favorable Tolerability
01/05/2022	DURANTE MANGONI Emanuele	Dalbavancin treatment of patients affected by ABSSSI and immediate discharge from the emergency department with the aid of a remote follow-up: a pilot study
18/11/2022	MARTINELLI Erika	A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC COLORECTAL CANCER"
14/11/2022	MARTINI Giulia	A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer
26/07/2022	NAPOLITANO Stefania	A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab versus investigator's choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation -AMG 50/20190172
10/05/2022	ROMANO Marco	A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum
20/10/2022	CIARDIELLO Fortunato	A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).

19/07/2022	CIARDIELLO Fortunato	CAVE-2 (cetuximab-avelumab) mCRC: Studio clinico di fase II, randomizzato sulla combinazione di avelumab e cetuximab come strategia di re-challenge in pazienti affetti da carcinoma del colon-retto metastatico, RAS/BRAF Wild Type precedentemente trattati
03/01/2022	CICCIA Francesco	CTECHRHEMA
13/10/2022	CICCIA Francesco	APATURA
01/03/2022	GRAVINA Antonietta Gerarda	Anti-Inflammatory Properties of a Nutraceutical Compound based on H. Erinaceus, Quercetin, and Berberine in Colic Mucosa Samples from Patients with Inflammatory Bowel Disease: An Ex Vivo Study
09/05/2022	ROMANO Marco	CESSA
25/11/2022	ROMANO Marco	PREPDIAL
25/11/2022	ROMANO Marco	Comparison of low volume versus high volume polyethylene glycol based bowel preparation for colonoscopy in people receiving hemodialysis<. A randomized non inferiority trial
20/07/2022	DURANTE MANGONI Emanuele	PROVE
03/03/2022	TROIANI Teresa	Retrospective-prospective observational study of Italian patients treated in melanoma adjuvant cohort MAP to evaluate relapse free survival and overall survival – MADAM (Maximing ADjuvAnt MAP)
03/03/2022	CIARDIELLO Fortunato	ItaLynch: “mainstreaming” della diagnosi della Sindrome di Lynch
15/09/2022	CICCIA Francesco	PSA-BIOND
15/06/2022	CICCIA Francesco	FILOSOPHY (FILgotinib Observational Study Of Patient Health-related Outcomes over 2 years NUMERO PROTOCOLLO: GLPG0634-CL-401
10/03/2022	CICCIA Francesco	APEX